ATRICURE INC
ATRCNASDAQTrading Snapshot
- Day Range
- $57.38 β $58.67
- 52-Week Range
- $25.36 β $61.70
- Volume
- $5.94B
- Avg Volume
- $6.42B
- Shares Outstanding
- 50.9M
- Next Earnings
- Dec 5, 2026
Fundamentals Snapshot
- Annual Revenue
- $535M
- Last Q Revenue
- $154M
- P/E Ratio
- 275.3
- P/S Ratio
- 5.2x
- EPS (TTM)
- $0.22
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +3.8%
Why Investors Own ATRC
- βHigh-growth profile β revenue up -5.1% YoY with expanding US Equity exposure.
- βHealthy economics β 49% gross margin and 29% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ATRICURE INC
ATRCAbout ATRICURE INC
AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX Pen, uniquely enable surgeons to evaluate cardiac arrhythmias, conduct temporary pacing, sensing, and stimulation, and perform tissue ablation with a single device. The Coolrail device facilitates the creation of longer linear ablation lines. For varying lengths of linear ablations, the CryoICE Cryoablation System is available. Furthermore, the EPi-Sense Guided Coagulation System is a single-use solution for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure also provides systems for cardiac appendage management and soft-tissue closure. The AtriClip System is an implantable device accompanied by a disposable applier, while the LARIAT System offers a suture-based solution for soft-tissue closure, compatible with various anatomical shapes. Additionally, AtriCure offers supplementary surgical tools including Lumitip Dissectors, designed to separate tissues for optimal access, Glidepath guides for precise clamp placement, and Subtle Cannulas facilitating access for EPi-Sense catheters. A suite of reusable cardiac surgery instruments, crucial for procedures involving heart valve repair or replacement, is also available. The company distributes its offerings through a combination of independent distributors and direct sales personnel. Founded in 2000, AtriCure maintains its headquarters in Mason, Ohio.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates

AtriCure (NASDAQ:ATRC) Reaches New 12-Month High β Hereβs What Happened
AtriCure, Inc. (NASDAQ: ATRC - Get Free Report) shares reached a new 52-week high during trading on Wednesday. The company traded as high as $60.99 and last traded at $60.9210, with a volume of 76652 shares traded. The s

Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?
Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

AtriCure CTO Sells 3,657 Shares
The transaction was valued at $201,000. The sale represented 2% of the insider's direct equity holdings prior to the transaction.

Do Options Traders Know Something About AtriCure Stock We Don't?
Investors need to pay close attention to ATRC stock based on the movements in the options market lately.

AtriCure, Inc. (ATRC) Hit a 52 Week High, Can the Run Continue?
AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?
Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.